Sites are dynamic environments, and new technology and industry initiatives are an important complement to the critical need for relationship building and maintenance. But are they helping improve sponsors and CROs collaboration with sites, or enabling them to become more competitive through improved clinical trial performance?
Metrics are critical to efforts for reining in clinical trials that are either poorly initiated or have incurred unforeseen events which place the original timelines and/or budgets at risk of overages. They also drive competitive performance among those organizations performing trials.
The focus on technology as a driver of performance improvement in clinical trials in intense, but despite years of valiant efforts, study execution remains far from optimal. For study startup, the data are dismal.
Where are the bottlenecks in starting clinical trials? It’s an obvious question to ask, but unfortunately, the tools traditionally used to conduct clinical trials lack robust reporting capabilities. Today, BI initiatives continue to top sponsor and CRO priorities, as executives demand greater visibility into trial data at a much faster pace.
The clinical trials sector is heavily invested in technologies that track how studies unfold. But, putting that information to good use requires turning real-time visibility into actionable data. Until recently, use of BI in clinical trials has been far from commonplace. But that is beginning to change, driven largely by a need to revamp how studies are conducted in today’s ultra-competitive global marketplace.